Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Icatolimab |
Synonyms | |
Therapy Description |
Icatolimab (JS004) is a humanized monoclonal antibody that binds to B- and T-lymphocyte attenuator (BTLA) and activates T-cells, thereby potentially resulting in the activation of antitumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 2643). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Icatolimab | JS004|JS-004|JS 004|TAB004|TAB-004|TAB 004|Tifcemalimab | Icatolimab (JS004) is a humanized monoclonal antibody that binds to B- and T-lymphocyte attenuator (BTLA) and activates T-cells, thereby potentially resulting in the activation of antitumor immune response (J Clin Oncol 40, no. 16_suppl (June 01, 2022) 2643). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04137900 | Phase I | Icatolimab | Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies | Recruiting | USA | 0 |